{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:27:58Z","timestamp":1790263678952,"version":"4.1.0"},"reference-count":31,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,1,3]],"date-time":"2015-01-03T00:00:00Z","timestamp":1420243200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2015,1,3]],"date-time":"2015-01-03T00:00:00Z","timestamp":1420243200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Blood Cancer"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1002\/pbc.25344","type":"journal-article","created":{"date-parts":[[2015,1,3]],"date-time":"2015-01-03T15:37:22Z","timestamp":1420299442000},"page":"603-610","source":"Crossref","is-referenced-by-count":19,"title":["Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors"],"prefix":"10.1002","volume":"62","author":[{"given":"Srivandana","family":"Akshintala","sequence":"first","affiliation":[{"name":"Pediatric Oncology Branch; Center for Cancer Research; National Cancer Institute; National Institutes of Health; Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh","family":"Marcus","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch; Center for Cancer Research; National Cancer Institute; National Institutes of Health; Bethesda Maryland"},{"name":"Center for Cancer and Blood Disorders; Children's National Medical Center; Washington District of Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.","family":"Warren","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch; Center for Cancer Research; National Cancer Institute; National Institutes of Health; Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Murphy","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch; Center for Cancer Research; National Cancer Institute; National Institutes of Health; Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan M.","family":"Sissung","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Program; Office of the Clinical Director, National Cancer Institute; Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Program; Office of the Clinical Director, National Cancer Institute; Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy J.","family":"Goodspeed","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch; Center for Cancer Research; National Cancer Institute; National Institutes of Health; Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Goodwin","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch; Center for Cancer Research; National Cancer Institute; National Institutes of Health; Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen C.","family":"Brewer","sequence":"additional","affiliation":[{"name":"National Institute on Deafness and Other Communication Disorders; Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Zalewski","sequence":"additional","affiliation":[{"name":"National Institute on Deafness and Other Communication Disorders; Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly A.","family":"King","sequence":"additional","affiliation":[{"name":"National Institute on Deafness and Other Communication Disorders; Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AeRang","family":"Kim","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch; Center for Cancer Research; National Cancer Institute; National Institutes of Health; Bethesda Maryland"},{"name":"Center for Cancer and Blood Disorders; Children's National Medical Center; Washington District of Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Figg","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Program; Office of the Clinical Director, National Cancer Institute; Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte C.","family":"Widemann","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch; Center for Cancer Research; National Cancer Institute; National Institutes of Health; Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,1,3]]},"reference":[{"key":"10.1002\/pbc.25344-BIB0001|pbc25344-cit-0001","first-page":"1780","volume-title":"Principles and practice of pediatric oncology","author":"Pizzo","year":"2006"},{"key":"10.1002\/pbc.25344-BIB0002|pbc25344-cit-0002","unstructured":"Satraplatin Investigator's Brochure version 6 2012"},{"key":"10.1002\/pbc.25344-BIB0003|pbc25344-cit-0003","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1586\/14737140.6.7.973","article-title":"Satraplatin: An orally available platinum analog for the treatment of cancer","volume":"6","author":"Choy","year":"2006","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1002\/pbc.25344-BIB0004|pbc25344-cit-0004","first-page":"2581","article-title":"Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): An orally active platinum drug","volume":"53","author":"Kelland","year":"1993","journal-title":"Cancer Res"},{"key":"10.1002\/pbc.25344-BIB0005|pbc25344-cit-0005","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.bcp.2006.06.008","article-title":"Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells","volume":"72","author":"Martelli","year":"2006","journal-title":"Biochem Pharmacol"},{"key":"10.1002\/pbc.25344-BIB0006|pbc25344-cit-0006","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/bjc.1993.322","article-title":"In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin","volume":"68","author":"Mellish","year":"1993","journal-title":"Br J Cancer"},{"key":"10.1002\/pbc.25344-BIB0007|pbc25344-cit-0007","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/bjc.1994.320","article-title":"Evaluation of novel ammine\/amine platinum (IV) dicarboxylates in L1210 murine leukaemia cells sensitive and resistant to cisplatin, tetraplatin or carboplatin","volume":"70","author":"Orr","year":"1994","journal-title":"Br J Cancer"},{"key":"10.1002\/pbc.25344-BIB0008|pbc25344-cit-0008","first-page":"5674","article-title":"Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin","volume":"52","author":"Twentyman","year":"1992","journal-title":"Cancer Res"},{"key":"10.1002\/pbc.25344-BIB0009|pbc25344-cit-0009","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00280-007-0502-z","article-title":"Preclinical antitumor activity of the oral platinum analog satraplatin","volume":"60","author":"Wosikowski","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1002\/pbc.25344-BIB0010|pbc25344-cit-0010","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s002800050797","article-title":"Phase I study of oral JM216 given twice daily","volume":"42","author":"Beale","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1002\/pbc.25344-BIB0011|pbc25344-cit-0011","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/jjco\/hyd102","article-title":"Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: A phase I study","volume":"30","author":"Kurata","year":"2000","journal-title":"Jpn J Clin Oncol"},{"key":"10.1002\/pbc.25344-BIB0012|pbc25344-cit-0012","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.1997.15.7.2691","article-title":"Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer","volume":"15","author":"McKeage","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.25344-BIB0013|pbc25344-cit-0013","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1023\/A:1008441416790","article-title":"Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days","volume":"9","author":"Sessa","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1002\/pbc.25344-BIB0014|pbc25344-cit-0014","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.1999.17.12.3822","article-title":"Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer","volume":"17","author":"Fokkema","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.25344-BIB0015|pbc25344-cit-0015","first-page":"79","article-title":"Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216","volume":"23","author":"Latif","year":"2005","journal-title":"BMS-1827 51) given daily x 5 in hormone refractory prostate cancer (HRPC). Invest New Drugs"},{"key":"10.1002\/pbc.25344-BIB0016|pbc25344-cit-0016","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1200\/JCO.2008.20.1228","article-title":"Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: The SPARC trial","volume":"27","author":"Sternberg","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.25344-BIB0017|pbc25344-cit-0017","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1158\/1078-0432.CCR-08-2373","article-title":"Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: A pharmacokinetic and food effect study","volume":"15","author":"Ricart","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1002\/pbc.25344-BIB0018|pbc25344-cit-0018","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/jnci\/92.3.179","article-title":"Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)","volume":"92","author":"Gehan","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1002\/pbc.25344-BIB0019|pbc25344-cit-0019","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1002\/pbc.25344-BIB0020|pbc25344-cit-0020","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00280-011-1659-z","article-title":"The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates","volume":"69","author":"Marcus","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1002\/pbc.25344-BIB0021|pbc25344-cit-0021","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/bjc.1998.649","article-title":"Potent and non-specific inhibition of cytochrome P450 by JM216, a new oral platinum agent","volume":"78","author":"Ando","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1002\/pbc.25344-BIB0022|pbc25344-cit-0022","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00280-005-0069-5","article-title":"Satraplatin activation by haemoglobin, cytochrome C and liver microsomes in vitro","volume":"57","author":"Carr","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1002\/pbc.25344-BIB0023|pbc25344-cit-0023","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/annonc\/mdr358","article-title":"Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors","volume":"23","author":"Galsky","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1002\/pbc.25344-BIB0024|pbc25344-cit-0024","first-page":"1857","article-title":"Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products","volume":"16","author":"Raynaud","year":"1996","journal-title":"Anticancer Res"},{"key":"10.1002\/pbc.25344-BIB0025|pbc25344-cit-0025","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.canlet.2014.01.005","article-title":"Nucleotide excision repair: Why is it not used to predict response to platinum-based chemotherapy?","volume":"346","author":"Bowden","year":"2014","journal-title":"Cancer Lett"},{"key":"10.1002\/pbc.25344-BIB0026|pbc25344-cit-0026","first-page":"435","article-title":"Predictive role of repair enzymes in the efficacy of Cisplatin combinations in pancreatic and lung cancer","volume":"34","author":"Peters","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1002\/pbc.25344-BIB0027|pbc25344-cit-0027","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1158\/1078-0432.CCR-10-2169","article-title":"ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis","volume":"17","author":"Yin","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1002\/pbc.25344-BIB0028|pbc25344-cit-0028","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.clgc.2013.04.007","article-title":"Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: A pharmacogenetic assessment of outcome and toxicity","volume":"11","author":"Figg","year":"2013","journal-title":"Clin Genitourin Cancer"},{"key":"10.1002\/pbc.25344-BIB0029|pbc25344-cit-0029","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1200\/JCO.2011.39.1110","article-title":"Platinum-induced ototoxicity in children: A consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale","volume":"30","author":"Brock","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.25344-BIB0030|pbc25344-cit-0030","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/BF00685793","article-title":"A phase I and pharmacology study of an oral platinum complex, JM216: Dose-dependent pharmacokinetics with single-dose administration","volume":"36","author":"McKeage","year":"1995","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1002\/pbc.25344-BIB0031|pbc25344-cit-0031","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1200\/JCO.2008.16.7585","article-title":"Phase I study of weekly oxaliplatin in relapsed or refractory pediatric solid malignancies","volume":"26","author":"Geoerger","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Pediatric Blood & Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.25344","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.25344","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/pbc.25344\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T10:48:41Z","timestamp":1596106121000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/pbc.25344"}},"subtitle":["Satraplatin pediatric phase 1 trial"],"short-title":[],"issued":{"date-parts":[[2015,1,3]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"URL":"https:\/\/doi.org\/10.1002\/pbc.25344","archive":["Portico"],"relation":{},"ISSN":["1545-5009"],"issn-type":[{"value":"1545-5009","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1,3]]}}}